Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis

Yuiko Sato, Toshimi Tando, Mayu Morita, Kana Miyamoto, Tami Kobayashi, Ryuichi Watanabe, Takatsugu Oike, Morio Matsumoto, Masaya Nakamura, Takeshi Miyamoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Rapid increases in the number of elderly people have dramatically increased the number of female and male osteoporosis patients. Osteoporosis often causes bone fragility fractures, and males exhibit particularly poor prognosis after these fractures, indicating that control of osteoporosis is crucial to maintain quality of men's lives. However, osteoporosis therapies available for men have lagged behind advances available for women. Here, we show that three selective estrogen receptor modulators (SERMs), namely, raloxifene, bazedoxifene, and tamoxifen, plus the vitamin D analogue ED71, also called eldecalcitol, completely block orchiectomy-induced, testosterone-depleted bone loss in male mice in vivo. Patients treated with hormone deprivation therapy for prostate cancer also exhibit male osteoporosis, and bone management is critical for these patients. Given that androgen replacement therapy is not an option for these patients, our results represent a novel approach potentially useful to control male osteoporosis.

Original languageEnglish
Pages (from-to)1430-1436
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume482
Issue number4
DOIs
Publication statusPublished - 2017 Jan 22

Keywords

  • Bazedoxifene
  • Eldecalcitol
  • Male osteoporosis
  • Raloxifene
  • Selective estrogen receptor modulators
  • Tamoxifen

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis'. Together they form a unique fingerprint.

  • Cite this